KEDI Global Obesity Care Industry Top 2+ Index

Novo Nordisk is scheduled to hold its Capital Markets Day in London on 21 September 2026.

Heidi O’Neill is scheduled to become lululemon’s Chief Executive Officer and join its board effective September 8, 2026.

Thomas Dittrich is scheduled to become Amgen's executive vice president and chief financial officer on September 1, 2026, succeeding retiring CFO Peter Griffith.

Detailed Phase III CARDIO-TTRansform results for Wainua (eplontersen) are scheduled for presentation at ESC Congress 2026 in Munich on 28-31 August.

DICK'S Sporting Goods tentatively plans to publish its second-quarter 2026 earnings results on August 25, 2026.

Eli Lilly will announce second-quarter 2026 financial results and hold its earnings call on August 5, 2026.

Novo Nordisk is scheduled to announce its first-half 2026 financial results on 5 August 2026 at 07:30 CEST.

Amgen has officially scheduled its Q2 2026 earnings conference call for August 4, 2026 at 1:30 p.m. PDT, following the U.S. market close.

Merck is scheduled to release second-quarter 2026 sales and earnings and hold its investor conference call on August 4, 2026.

Merck is scheduled to hold a virtual HIV Investor Event on August 3, 2026, at which senior management will update investors on the company’s HIV program and strategy.

Life Time is scheduled to release second-quarter 2026 financial results before market open on July 30, 2026.

AstraZeneca is scheduled to publish its H1 and Q2 2026 financial results before market open on 27 July 2026.

Novo Nordisk sought a preliminary US court injunction to halt Eli Lilly advertisements for Zepbound and Mounjaro while its false-advertising case proceeds.

AstraZeneca's Etcamah (camizestrant) was approved in the EU with a CDK4/6 inhibitor for first-line ER-positive, HER2-negative advanced breast cancer with an emergent ESR1 mutation.

Amgen submitted data and analyses to the FDA on July 23, 2026 in support of a hearing request challenging CDER's proposed withdrawal of TAVNEOS approval.

Eli Lilly reported positive Phase 3 TRIUMPH-2 and TRIUMPH-3 topline results for retatrutide, with a U.S. BLA submission planned for the first quarter of 2027.

Amgen agreed to a proposed $74 million settlement of an investor class action concerning disclosures of its potential IRS tax liability.

Merck and Gilead reported that once-weekly oral islatravir/lenacapavir maintained virologic suppression at Week 48 in both Phase 3 ISLEND trials.

Novartis confirmed that a BLA for accelerated approval of del-zota in Duchenne muscular dystrophy amenable to exon 44 skipping was submitted to the FDA.

Novartis reported clinically meaningful six-year overall-survival data for Kisqali in early breast cancer and said the FDA granted six months of pediatric exclusivity across its Orange Book-listed patents.

Novartis said it completed US and EU submissions for traditional approval of Vanrafia in adults with primary IgA nephropathy.

Novartis reported Q2 2026 core EPS of $2.41 and net sales of $14.41 billion, exceeding consensus estimates and reaffirming full-year guidance.